Trial Profile
Thorough QT/QTc study for Garenoxacin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Garenoxacin (Primary) ; Moxifloxacin (Primary)
- Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Gram-negative infections; Gram-positive infections; Intra-abdominal infections; Otorhinolaryngological infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Schering-Plough
- 03 Apr 2022 Status changed from recruiting to completed.
- 11 Jul 2011 New trial record